ACE2 News and Research

RSS

Brain pericytes serve as a potential hub for SARS-CoV-2 infection

A team of scientists from the United States has recently conducted a study using pericyte-like cell-containing brain cortical organoids as an experimental model to investigate the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on the central nervous system.

11 Feb 2021

Higher proportion of male children develop COVID-19-related Multisystem Inflammatory Syndrome, finds study

Previous studies about COVID-19 have shown that the illness is often more severe in men than women. However, there is limited data available for the pediatric population. Though children and adolescents are at a lower risk of developing severe illness, some may experience severe symptoms. In some cases, children develop complications, including the multisystem inflammatory syndrome in children (MIS-C). Researchers report that a higher percentage of male children developed MIS-C and died.

11 Feb 2021

Second dose of Pfizer-BioNTech COVID-19 vaccine may not benefit previously infected individuals

Researchers at the NYU Grossman School of Medicine have shown that a second dose of the Pfizer-BioNTech BNT162b2 vaccine may not offer any additional protection against coronavirus disease 2019 (COVID-19) over one dose among individuals previously infected with the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

10 Feb 2021

Substrain of SARS-CoV-2 variant in UK may resist antibody neutralization

Researchers at the Polish Academy of Sciences in Warsaw have identified a substrain of the recently emerged B.1.1.7 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may confer resistance to antibody neutralization.

10 Feb 2021

Study shows local topological free energy as determinant of SARS-CoV-2 spike stability

A recent study conducted by US scientists has demonstrated that the distribution of local topological free energy along the spike protein domains of SARS-CoV-2 is associated with their activity in protein rearrangement.

10 Feb 2021

Could a SARS-CoV-2 accessory protein be responsible for certain COVID-19 symptoms?

Researchers highlight the potential causes of some COVID-19 symptoms. Early in the pandemic, the hallmark symptoms of COVID-19 include cough, fever, and shortness of breath. As the pandemic has evolved, more symptoms have emerged, such as loss of smell and taste, headache, intestinal issues, and abdominal pains.

10 Feb 2021

Polyclonal SARS-CoV-2 antibody shows potent neutralizing activity in vitro

Researchers shows a fully human immunoglobulin (IgG) that potently inhibits SARS-CoV-2 infection.

10 Feb 2021

Study finds low SARS-CoV-2 antibody responses in asymptomatic and mild COVID-19 cases

Researchers at Northwestern University have noted high rates of asymptomatic and mild infection in a large community-based cohort and low levels of anti-SARS-CoV-2 immunoglobulin G antibody (IgG) in the general population of previously exposed people.

10 Feb 2021

Both mRNA vaccines protect against emerging variants of SARS-CoV-2

Researchers in the United States and Canada have conducted a study showing that just a single dose of either the Pfizer-BioNTech or Moderna vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is likely to protect against emerging variants.

9 Feb 2021

Pfizer-BioNTech COVID-19 vaccine effective against variants, study shows

Researchers at NYU Grossman School of Medicine in New York have conducted a study demonstrating the effectiveness of the Pfizer-BioNtech BNT162b2 vaccine against recently emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

9 Feb 2021

Smell and taste loss symptoms associated with robust SARS-CoV-2 antibody response in new study

Researchers in Italy report a correlation between the loss of smell and taste and an observed persistence or rise in antibody levels at five months after infection.

9 Feb 2021

Inhibition of protein glycosylation successfully prevents SARS-CoV-2 infection in vitro

A new study provides direct evidence that the oligosaccharides attached to the viral surface spike protein are essential for viral infection, offering new approaches to preventive and therapeutic drugs.

9 Feb 2021

Emergence and transmission of UK SARS-CoV-2 variant in the US

Researchers describe the impending rise to dominance of the B.1.1.7 (UK) variant in the US. Understanding this development will help to shape preventive action to reduce the infection and mortality rates.

9 Feb 2021

Researchers find new clues to how SARS-CoV-2 infects cells

The molecular details of how SARS-CoV-2 enters cells and infects them are still not clear. Researchers at Uppsala University have tested the bioinformatic predictions made by another research group and have identified receptors that could be important players in the process.

8 Feb 2021

Moderna's COVID-19 vaccine effective against emerging variants

Researchers have conducted a study showing that the Moderna mRNA-1273 vaccine effectively protects against recently emerged variants of SARS-CoV-2 – the agent that causes COVID-19.

8 Feb 2021

Scientists produce active antigen in bacteria to help combat SARS-CoV-2

Researchers at the University of Nebraska Medical Center have developed a bacterial strategy for the expression and purification of the SARS-CoV-2 spike protein receptor-binding domain (RBD).

8 Feb 2021

Furin cleavage SARS-CoV-2 spike deletions mostly suppressed within infected airway epithelium, says study

A team of researchers recently examined the SARS-CoV-2 transcriptome and the dynamics of the S gene furin cleavage site in primary human airway epithelia.

8 Feb 2021

Bioengineered ankyrin compounds show high in vitro activity against SARS-CoV-2 mutants

A new study describes the use of DARPin (designed ankyrin repeat proteins) therapeutic agents, each of which contains three different DARPin domains within the same molecule.

8 Feb 2021

Could graphene be an effective antiviral platform against SARS-CoV-2?

The urgent need for novel therapeutics has spurred investigation into broad-spectrum inhibitors of viral infection and replication. A new study describes the antiviral activity of synthesized graphene platforms, pointing to new therapeutic approaches against this virus.

8 Feb 2021

SARS-CoV-2 escape mutations identified against monoclonal antibodies and polyclonal immune sera

A recent study describes the experimental selection of SARS-CoV-2 mutants associated with resistance to antibodies, with important implications for vaccine development and therapeutic antibody use.

8 Feb 2021

ACE2 News and Research

Brain pericytes serve as a potential hub for SARS-CoV-2 infection

Higher proportion of male children develop COVID-19-related Multisystem Inflammatory Syndrome, finds study

Second dose of Pfizer-BioNTech COVID-19 vaccine may not benefit previously infected individuals

Substrain of SARS-CoV-2 variant in UK may resist antibody neutralization

Study shows local topological free energy as determinant of SARS-CoV-2 spike stability

Could a SARS-CoV-2 accessory protein be responsible for certain COVID-19 symptoms?

Polyclonal SARS-CoV-2 antibody shows potent neutralizing activity in vitro

Study finds low SARS-CoV-2 antibody responses in asymptomatic and mild COVID-19 cases

Both mRNA vaccines protect against emerging variants of SARS-CoV-2

Pfizer-BioNTech COVID-19 vaccine effective against variants, study shows

Smell and taste loss symptoms associated with robust SARS-CoV-2 antibody response in new study

Inhibition of protein glycosylation successfully prevents SARS-CoV-2 infection in vitro

Emergence and transmission of UK SARS-CoV-2 variant in the US

Researchers find new clues to how SARS-CoV-2 infects cells

Moderna's COVID-19 vaccine effective against emerging variants

Scientists produce active antigen in bacteria to help combat SARS-CoV-2

Furin cleavage SARS-CoV-2 spike deletions mostly suppressed within infected airway epithelium, says study

Bioengineered ankyrin compounds show high in vitro activity against SARS-CoV-2 mutants

Could graphene be an effective antiviral platform against SARS-CoV-2?

SARS-CoV-2 escape mutations identified against monoclonal antibodies and polyclonal immune sera

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News